← Back to Clinical Trials
Recruiting NCT06090383

NCT06090383 Feasibility and Discriminant Validity of Monitoring Movement Behavior of Adolescents With Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06090383
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Cerebral Palsy (CP)
Study Type OBSERVATIONAL
Enrollment 25 participants
Start Date 2023-10-16
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 25 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 25 participants in total. It began in 2023-10-16 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A new artificial intelligence network has been developed to monitor real-world daytime and nighttime movement behavior of adolescents with cerebral palsy (CP). The network uses seven wearable sensors to recognize lying, sitting, and standing, as well as walking and movements of both arms and legs. This information can be useful for healthcare professionals to understand and influence change in movement behavior, leading to benefits for the health of adolescents with cerebral palsy. This study aims to examine the acceptability and technical dependability of monitoring the movement behavior of adolescents with cerebral palsy for 72 hours using wearable sensors. Additionally, the study aims to evaluate the network's ability to discriminate between control and individuals with CP, different subgroups of individuals with CP, as well as the incidence of sleep disturbance in the entire cohort.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of Cerebral Palsy at GMFCS-E\&R levels I-V and typically developed without neurological impairment. * Age range: 15-25 years * Capable of providing informed consent or have a legal guardian who can provide consent on their behalf. Exclusion Criteria: * Adolescents without the capacity to provide informed consent when another young adult with the capacity can provide the same or similar data. * Adolescents who have undergone musculoskeletal surgery or injury and have not resumed their normal movement behavior. * Presence of skin wounds in areas where sensors are to be attached.

Contact & Investigator

Central Contact

Ivana Bardino Novosel, Ph.d. student

✉ ivana.novosel@sund.ku.dk

📞 +4527328961

Principal Investigator

Jakob Lorentzen, Prof.

PRINCIPAL INVESTIGATOR

University of Copenhagen, Department of Neuroscience

Frequently Asked Questions

Who can join the NCT06090383 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 25 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06090383 currently recruiting?

Yes, NCT06090383 is actively recruiting participants. Contact the research team at ivana.novosel@sund.ku.dk for enrollment information.

Where is the NCT06090383 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT06090383 clinical trial?

NCT06090383 is sponsored by Rigshospitalet, Denmark. The principal investigator is Jakob Lorentzen, Prof. at University of Copenhagen, Department of Neuroscience. The trial plans to enroll 25 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology